Compare CECO & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CECO | VCEL |
|---|---|---|
| Founded | 1966 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | N/A | 1997 |
| Metric | CECO | VCEL |
|---|---|---|
| Price | $60.99 | $37.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $50.75 | ★ $57.50 |
| AVG Volume (30 Days) | 306.4K | ★ 682.8K |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 334.15 | 236.54 |
| EPS | ★ 1.43 | 0.25 |
| Revenue | ★ $718,253,000.00 | $258,716,999.00 |
| Revenue This Year | $39.58 | $17.86 |
| Revenue Next Year | $14.60 | $18.55 |
| P/E Ratio | ★ $42.17 | $151.53 |
| Revenue Growth | ★ 29.86 | 14.05 |
| 52 Week Low | $17.57 | $29.24 |
| 52 Week High | $63.98 | $63.00 |
| Indicator | CECO | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 64.69 | 50.63 |
| Support Level | $56.30 | $35.53 |
| Resistance Level | $63.98 | $38.09 |
| Average True Range (ATR) | 2.63 | 1.35 |
| MACD | 0.15 | -0.07 |
| Stochastic Oscillator | 69.22 | 67.14 |
CECO Environmental Corp serves the energy, industrial, and other niche markets. The company operates through the Engineered Systems segment that serves the power generation, refinery, water/wastewater, and midstream oil and gas markets, and Industrial Process Solutions segment, which serves the broad industrial air pollution control, beverage can, fluid handling, electric vehicle production, food and beverage, semi-conductor, process filtration, pharmaceutical, petrochemical, wastewater treatment, wood manufacturing, desalination, and aquaculture markets. The majority of revenue is earned from the Engineered Systems Segment.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.